

Briony Larance

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9000603/publications.pdf>

Version: 2024-02-01

71
papers

1,770
citations

279798

23
h-index

302126

39
g-index

73
all docs

73
docs citations

73
times ranked

1852
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Economic analysis of out-of-pocket costs among people in opioid agonist treatment: A cross-sectional survey in three Australian jurisdictions. <i>International Journal of Drug Policy</i> , 2022, 99, 103472. | 3.3 | 11 |
| 2 | Outcomes of a single-arm implementation trial of extended-release subcutaneous buprenorphine depot injections in people with opioid dependence. <i>International Journal of Drug Policy</i> , 2022, 100, 103492. | 3.3 | 22 |
| 3 | Examining the cost and impact of dosing fees among clients in opioid agonist treatment: Results from a cross-sectional survey of Australian treatment clients. <i>Drug and Alcohol Review</i> , 2022, 41, 841-850. | 2.1 | 7 |
| 4 | Self-reported challenges obtaining ongoing prescription opioids among Australians with chronic non-cancer pain. <i>International Journal of Drug Policy</i> , 2022, 105, 103708. | 3.3 | 2 |
| 5 | Systematic review of guidelines for managing physical health during treatment for substance use disorders: Implications for the alcohol and other drug workforce. <i>Drug and Alcohol Review</i> , 2022, 41, 1367-1390. | 2.1 | 3 |
| 6 | Facilitators and barriers to integrating physical health care during treatment for substance use: A socio-ecological analysis. <i>Drug and Alcohol Review</i> , 2021, 40, 607-616. | 2.1 | 7 |
| 7 | Characteristics and circumstances of death related to buprenorphine toxicity in Australia. <i>Drug and Alcohol Dependence</i> , 2021, 218, 108360. | 3.2 | 7 |
| 8 | Routine outcome measurement in specialist non-government alcohol and other drug treatment services: Establishing effectiveness indicators for the <scp>NADA</scp>base. <i>Drug and Alcohol Review</i> , 2021, 40, 540-552. | 2.1 | 9 |
| 9 | Pharmaceutical Opioid Use Patterns and Indicators of Extramedical Use and Harm in Adults With Chronic Noncancer Pain, 2012-2018. <i>JAMA Network Open</i> , 2021, 4, e213059. | 5.9 | 4 |
| 10 | SMART Recovery International and COVID-19: Expanding the reach of mutual support through online groups. <i>Journal of Substance Abuse Treatment</i> , 2021, 131, 108568. | 2.8 | 11 |
| 11 | The use of Australian SMART Recovery groups by people who use methamphetamine: Analysis of routinely-collected nationwide data. <i>Drug and Alcohol Dependence</i> , 2021, 225, 108814. | 3.2 | 4 |
| 12 | Preliminary psychometric evaluation of the patient reported experience measure for addiction treatment (PREMAT). <i>Addictive Behaviors</i> , 2021, 123, 107048. | 3.0 | 1 |
| 13 | Perceptions of injectable opioid agonist treatment (iOAT) among people who regularly use opioids in Australia: findings from a cross-sectional study in three Australian cities. <i>Addiction</i> , 2021, 116, 1482-1494. | 3.3 | 3 |
| 14 | Feasibility of a Mobile Health App for Routine Outcome Monitoring and Feedback in SMART Recovery Mutual Support Groups: Stage 1 Mixed Methods Pilot Study. <i>Journal of Medical Internet Research</i> , 2021, 23, e25217. | 4.3 | 8 |
| 15 | Development of a Brief Patient-Administered Screening Tool for Prescription Opioid Dependence for Primary Care Settings. <i>Pain Medicine</i> , 2020, 21, e79-e88. | 1.9 | 8 |
| 16 | Substance Use and Co-occurring Physical Health Problems: File Review of a Residential Drug and Alcohol Treatment Service. <i>Journal of Dual Diagnosis</i> , 2020, 16, 250-259. | 1.2 | 11 |
| 17 | Correlates of indicators of potential extra-medical opioid use in people prescribed opioids for chronic non-cancer pain. <i>Drug and Alcohol Review</i> , 2020, 39, 128-134. | 2.1 | 7 |
| 18 | Opioid use and harms associated with a sustained-release tapentadol formulation: A post-marketing surveillance study. <i>Drug and Alcohol Dependence</i> , 2020, 206, 107697. | 3.2 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Perceptions of extended-release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia. <i>Addiction</i> , 2020, 115, 1295-1305. | 3.3 | 46 |
| 20 | Risk factors for indicators of opioid-related harms amongst people living with chronic non-cancer pain: Findings from a 5-year prospective cohort study. <i>EClinicalMedicine</i> , 2020, 28, 100592. | 7.1 | 16 |
| 21 | Open-label, multicentre, single-arm trial of monthly injections of depot buprenorphine in people with opioid dependence: protocol for the CoLAB study. <i>BMJ Open</i> , 2020, 10, e034389. | 1.9 | 9 |
| 22 | Feasibility of a Mobile Health App for Routine Outcome Monitoring and Feedback in Mutual Support Groups Coordinated by SMART Recovery Australia: Protocol for a Pilot Study. <i>JMIR Research Protocols</i> , 2020, 9, e15113. | 1.0 | 8 |
| 23 | Concerns and Help-Seeking Among Patients Using Opioids for Management of Chronic Noncancer Pain. <i>Pain Medicine</i> , 2019, 20, 758-769. | 1.9 | 9 |
| 24 | Post-marketing studies of pharmaceutical opioid abuse-deterrent formulations: a framework for research design and reporting. <i>Addiction</i> , 2019, 114, 389-399. | 3.3 | 11 |
| 25 | Circumstances of death of opioid users being treated with naltrexone. <i>Addiction</i> , 2019, 114, 2000-2007. | 3.3 | 6 |
| 26 | Effectiveness and framing of pharmaceutical opioid abuse-deterrent formulations. <i>Addiction</i> , 2019, 114, 404-405. | 3.3 | 2 |
| 27 | Regulatory and other responses to the pharmaceutical opioid problem. <i>Medical Journal of Australia</i> , 2019, 210, 6. | 1.7 | 36 |
| 28 | Trends in methamphetamine and opioid use among clients of needle-syringe programs in Queensland, Australia: 2007-2015. <i>Drug and Alcohol Review</i> , 2019, 38, 159-168. | 2.1 | 0 |
| 29 | Increases in controlled-release oxycodone utilisation following the subsidy of oxycodone with naloxone formulations: An Australian population-based study. <i>Pharmacoepidemiology and Drug Safety</i> , 2019, 28, 97-105. | 1.9 | 6 |
| 30 | A population-based study of transdermal fentanyl initiation in Australian clinical practice. <i>European Journal of Clinical Pharmacology</i> , 2019, 75, 401-408. | 1.9 | 8 |
| 31 | The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study. <i>Lancet Psychiatry</i> , 2018, 5, 155-166. | 7.4 | 28 |
| 32 | Person-level changes in oxycodone use after the introduction of a tamper-resistant formulation in Australia. <i>Cmaj</i> , 2018, 190, E355-E362. | 2.0 | 9 |
| 33 | Opioid use and harms associated with a sustained-release tapentadol formulation: a postmarketing study protocol. <i>BMJ Open</i> , 2018, 8, e020006. | 1.9 | 3 |
| 34 | Prescription Opioid Access Patterns and Factors Associated with Increasing Number of Prescribers, Pharmacies, and Dispensings: An Observational Study Using Pharmaceutical Claims. <i>Pain Medicine</i> , 2018, 19, 1170-1183. | 1.9 | 6 |
| 35 | To what extent do data from pharmaceutical claims under-estimate opioid analgesic utilisation in Australia?. <i>Pharmacoepidemiology and Drug Safety</i> , 2018, 27, 550-555. | 1.9 | 35 |
| 36 | Pharmaceutical opioid use and harm in Australia: The need for proactive and preventative responses. <i>Drug and Alcohol Review</i> , 2018, 37, S203-S205. | 2.1 | 32 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Predictors of transitions across stages of heroin use and dependence prior to treatment-seeking among people in treatment for opioid dependence. <i>Drug and Alcohol Dependence</i> , 2018, 191, 145-151. | 3.2 | 18 |
| 38 | Defined daily doses (DDD) do not accurately reflect opioid doses used in contemporary chronic pain treatment. <i>Pharmacoepidemiology and Drug Safety</i> , 2017, 26, 587-591. | 1.9 | 39 |
| 39 | Geographic Variation in Health Service Use and Perceived Access Barriers for Australian Adults with Chronic Non-Cancer Pain Receiving Opioid Therapy. <i>Pain Medicine</i> , 2016, 17, 2003-2016. | 1.9 | 10 |
| 40 | Defining problematic pharmaceutical opioid use among people prescribed opioids for chronic noncancer pain: do different measures identify the same patients?. <i>Pain</i> , 2016, 157, 1489-1498. | 4.2 | 43 |
| 41 | The extent and correlates of community-based pharmaceutical opioid utilisation in Australia. <i>Pharmacoepidemiology and Drug Safety</i> , 2016, 25, 521-538. | 1.9 | 63 |
| 42 | Development of a brief tool for monitoring aberrant behaviours among patients receiving long-term opioid therapy: The Opioid-Related Behaviours In Treatment (ORBIT) scale. <i>Drug and Alcohol Dependence</i> , 2016, 159, 42-52. | 3.2 | 27 |
| 43 | Same-day use of opioids and other central nervous system depressants amongst people who tamper with pharmaceutical opioids: A retrospective 7-day diary study. <i>Drug and Alcohol Dependence</i> , 2016, 166, 125-133. | 3.2 | 11 |
| 44 | Diversion and injection of buprenorphine-naloxone film two years post-introduction in Australia. <i>Drug and Alcohol Review</i> , 2016, 35, 83-91. | 2.1 | 15 |
| 45 | An ecological study of the extent and factors associated with the use of prescription and over-the-counter codeine in Australia. <i>European Journal of Clinical Pharmacology</i> , 2016, 72, 469-494. | 1.9 | 37 |
| 46 | Pain, alcohol use disorders and risky patterns of drinking among people with chronic non-cancer pain receiving long-term opioid therapy. <i>Drug and Alcohol Dependence</i> , 2016, 162, 79-87. | 3.2 | 40 |
| 47 | The extramedical use and diversion of opioid substitution medications and other medications in prison settings in Australia following the introduction of buprenorphine-naloxone film. <i>Drug and Alcohol Review</i> , 2016, 35, 76-82. | 2.1 | 21 |
| 48 | The introduction of buprenorphine-naloxone film in opioid substitution therapy in Australia: Uptake and issues arising from changing buprenorphine formulations. <i>Drug and Alcohol Review</i> , 2015, 34, 603-610. | 2.1 | 8 |
| 49 | Injecting buprenorphine-naloxone film: Findings from an explorative qualitative study. <i>Drug and Alcohol Review</i> , 2015, 34, 623-629. | 2.1 | 6 |
| 50 | Jurisdictional differences in opioid use, other licit and illicit drug use, and harms associated with substance use among people who tamper with pharmaceutical opioids. <i>Drug and Alcohol Review</i> , 2015, 34, 611-622. | 2.1 | 10 |
| 51 | A typology of people who tamper with pharmaceutical opioids: responses to introduction of a tamper-resistant formulation of controlled-release oxycodone. <i>Pharmacoepidemiology and Drug Safety</i> , 2015, 24, 1321-1333. | 1.9 | 4 |
| 52 | Pharmaceutical Opioid Use and Dependence among People Living with Chronic Pain: Associations Observed within the Pain and Opioids in Treatment (POINT) Cohort. <i>Pain Medicine</i> , 2015, 16, 1745-1758. | 1.9 | 78 |
| 53 | Benzodiazepine Use among Chronic Pain Patients Prescribed Opioids: Associations with Pain, Physical and Mental Health, and Health Service Utilization. <i>Pain Medicine</i> , 2015, 16, 356-366. | 1.9 | 102 |
| 54 | The POPPY Research Programme protocol: investigating opioid utilisation, costs and patterns of extramedical use in Australia. <i>BMJ Open</i> , 2015, 5, e007030-e007030. | 1.9 | 9 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Methods and predictors of tampering with a tamper-resistant controlled-release oxycodone formulation. <i>International Journal of Drug Policy</i> , 2015, 26, 1265-1272. | 3.3 | 13 |
| 56 | The introduction of a potentially abuse deterrent oxycodone formulation: Early findings from the Australian National Opioid Medications Abuse Deterrence (NOMAD) study. <i>Drug and Alcohol Dependence</i> , 2015, 151, 56-67. | 3.2 | 29 |
| 57 | The Pain and Opioids IN Treatment study. <i>Pain</i> , 2015, 156, 231-242. | 4.2 | 104 |
| 58 | Evaluating the potential impact of a reformulated version of oxycodone upon tampering, non-adherence and diversion of opioids: the National Opioid Medications Abuse Deterrence (NOMAD) study protocol. <i>Addiction</i> , 2015, 110, 226-237. | 3.3 | 19 |
| 59 | A longitudinal comparison of retention in buprenorphine and methadone treatment for opioid dependence in New South Wales, Australia. <i>Addiction</i> , 2015, 110, 646-655. | 3.3 | 57 |
| 60 | The characteristics of a cohort who tamper with prescribed and diverted opioid medications. <i>Journal of Substance Abuse Treatment</i> , 2015, 58, 51-61. | 2.8 | 20 |
| 61 | Reducing extramedical use and harms of pharmaceutical opioids: the potential role of abuse-deterrent formulations. <i>Lancet Psychiatry</i> , 2015, 2, 957-959. | 7.4 | 3 |
| 62 | Diversion of prescribed opioids by people living with chronic pain: Results from an Australian community sample. <i>Drug and Alcohol Review</i> , 2014, 33, 27-32. | 2.1 | 11 |
| 63 | The diversion and injection of a buprenorphine-naloxone soluble film formulation. <i>Drug and Alcohol Dependence</i> , 2014, 136, 21-27. | 3.2 | 43 |
| 64 | Cohort protocol paper: The Pain and Opioids In Treatment (POINT) study. <i>BMC Pharmacology & Toxicology</i> , 2014, 15, 17. | 2.4 | 39 |
| 65 | A latent class analysis of self-reported clinical indicators of psychosocial stability and adherence among opioid substitution therapy patients: Do stable patients receive more unsupervised doses?. <i>Drug and Alcohol Dependence</i> , 2014, 142, 46-55. | 3.2 | 14 |
| 66 | Post-marketing surveillance of buprenorphine-naloxone in Australia: Diversion, injection and adherence with supervised dosing. <i>Drug and Alcohol Dependence</i> , 2011, 118, 265-273. | 3.2 | 62 |
| 67 | Prescription of opioid analgesics and related harms in Australia. <i>Medical Journal of Australia</i> , 2011, 195, 280-284. | 1.7 | 157 |
| 68 | Prescribers' perceptions of the diversion and injection of medication by opioid substitution treatment patients. <i>Drug and Alcohol Review</i> , 2011, 30, 613-620. | 2.1 | 21 |
| 69 | Definitions related to the use of pharmaceutical opioids: Extramedical use, diversion, non-adherence and aberrant medication-related behaviours. <i>Drug and Alcohol Review</i> , 2011, 30, 236-245. | 2.1 | 107 |
| 70 | The availability, diversion and injection of pharmaceutical opioids in South Asia. <i>Drug and Alcohol Review</i> , 2011, 30, 246-254. | 2.1 | 48 |
| 71 | Injecting risk behaviour and related harm among men who use performance and image enhancing drugs. <i>Drug and Alcohol Review</i> , 2008, 27, 679-686. | 2.1 | 77 |